>
Switch to:

Illumina PE Ratio without NRI

: 52.93 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2022-05-21), Illumina's share price is $243.49. Illumina's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $4.60. Therefore, Illumina's PE Ratio without NRI for today is 52.93.

During the past 13 years, Illumina's highest PE Ratio without NRI was 202.38. The lowest was 32.02. And the median was 65.18.

Illumina's EPS without NRI for the three months ended in Mar. 2022 was $0.55. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $4.60.

As of today (2022-05-21), Illumina's share price is $243.49. Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $. Therefore, Illumina's PE Ratio for today is N/A.

Good Sign:

Illumina Inc stock PE Ratio (=52.93) is close to 2-year low of 50.77

During the past years, Illumina's highest PE Ratio was 202.38. The lowest was 32.02. And the median was 65.18.

Illumina's EPS (Diluted)for the three months ended in Mar. 2022 was $0.55. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00.

Illumina's EPS (Basic) for the three months ended in Mar. 2022 was $0.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $4.63.


Illumina PE Ratio without NRI Historical Data

The historical data trend for Illumina's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PE Ratio without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.41 53.94 49.22 83.15 75.48

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
PE Ratio without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.73 90.65 66.60 75.48 75.96

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Illumina PE Ratio without NRI Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Illumina's PE Ratio without NRI falls into.



Illumina PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Illumina's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=243.49/4.600
=52.93

Illumina's Share Price of today is $243.49.
Illumina's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Illumina  (NAS:ILMN) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Illumina PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Illumina's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Illumina logo
Industry
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)